COVID-19 VACCINE-ASSOCIATED MYOCARDITIS (RUSSIAN TRANSLATION)
Myocarditis is now recognized as a rare complication of coronavirus disease 2019 (COVID-19) mRNA vaccination, particularly in adolescent and young adult males. Since the authorization of the Pfizer-BioNTech™ and Moderna™ mRNA vaccines targeting the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein, the Centers for Disease Control and Prevention (CDC) has reported 1175 confirmed cases of myocarditis after COVID-19 vaccination in individuals ages 30 years and younger as of January 2022. According to CDC data in June 2021, the incidence of vaccine-mediated myocarditis in males ages 12‑29 years old was estimated to be 40.6 cases per million second doses of COVID-19 mRNA vaccination administered. Individuals with cases of COVID-19 vaccine-mediated myocarditis typically present with acute chest pain and elevated serum troponin levels, often within one week of receiving the second dose of mRNA COVID-19 vaccination. Most cases follow a benign clinical course with prompt resolution of symptoms. Proposed mechanisms of COVID-19 vaccine myocarditis include molecular mimicry between SARS-CoV-2 spike protein and self-antigens and the triggering of preexisting dysregulated immune pathways in predisposed individuals. The higher incidence of COVID-19 vaccine myocarditis in young males may be explained by testosterone and its role in modulating the immune response in myocarditis. There is limited data on long-term outcomes in these cases given the recency of their occurrence. The CDC continues to recommend COVID-19 vaccination for everyone 5 years of age and older given the greater risk of serious complications related to natural COVID-19 infection including hospitalization, multisystem organ dysfunction, and death. Further study is needed to better understand the immunopathology and long-term outcomes behind COVID-19 mRNA vaccine-mediated myocarditis. Core Tip: In this review article, we aim to synthesize the current literature surrounding coronavirus disease 2019 (COVID-19) vaccine-mediated myocarditis. COVID-19 mRNA vaccination has been associated with increased cases of myocarditis, particularly in the adolescent and young adult male population. Presentation typically occurs several days following administration of the second dose of a COVID-19 mRNA vaccination. As the world continues to vaccinate against COVID-19, understanding this vaccine-related adverse event is clinically important. Potential mechanisms are reviewed, and current clinical recommendations are discussed. Original article: Morgan MC, Atri L, Harrell S, Al-Jaroudi W, Berman A. COVID-19 vaccine-associated myocarditis. World J Cardiol. 2022;14(7):382-391. DOI: 10.4330/wjc.v14.i7.382. The article was translated into Russian and published under the terms of the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Juvenis Scientia - 8(2022), 6, Seite 41-55 |
| Sprache: |
Englisch ; Russisch |
|---|
| Beteiligte Personen: |
M. C. Morgan [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Covid-19 |
|---|
| doi: |
10.32415/jscientia_2022_8_6_41-55 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ080506275 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ080506275 | ||
| 003 | DE-627 | ||
| 005 | 20230310191638.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230310s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.32415/jscientia_2022_8_6_41-55 |2 doi | |
| 035 | |a (DE-627)DOAJ080506275 | ||
| 035 | |a (DE-599)DOAJb1f8a1bd4a0d41d0a784d400b018aa86 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a rus | ||
| 050 | 0 | |a AZ20-999 | |
| 100 | 0 | |a M. C. Morgan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 VACCINE-ASSOCIATED MYOCARDITIS (RUSSIAN TRANSLATION) |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Myocarditis is now recognized as a rare complication of coronavirus disease 2019 (COVID-19) mRNA vaccination, particularly in adolescent and young adult males. Since the authorization of the Pfizer-BioNTech™ and Moderna™ mRNA vaccines targeting the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein, the Centers for Disease Control and Prevention (CDC) has reported 1175 confirmed cases of myocarditis after COVID-19 vaccination in individuals ages 30 years and younger as of January 2022. According to CDC data in June 2021, the incidence of vaccine-mediated myocarditis in males ages 12‑29 years old was estimated to be 40.6 cases per million second doses of COVID-19 mRNA vaccination administered. Individuals with cases of COVID-19 vaccine-mediated myocarditis typically present with acute chest pain and elevated serum troponin levels, often within one week of receiving the second dose of mRNA COVID-19 vaccination. Most cases follow a benign clinical course with prompt resolution of symptoms. Proposed mechanisms of COVID-19 vaccine myocarditis include molecular mimicry between SARS-CoV-2 spike protein and self-antigens and the triggering of preexisting dysregulated immune pathways in predisposed individuals. The higher incidence of COVID-19 vaccine myocarditis in young males may be explained by testosterone and its role in modulating the immune response in myocarditis. There is limited data on long-term outcomes in these cases given the recency of their occurrence. The CDC continues to recommend COVID-19 vaccination for everyone 5 years of age and older given the greater risk of serious complications related to natural COVID-19 infection including hospitalization, multisystem organ dysfunction, and death. Further study is needed to better understand the immunopathology and long-term outcomes behind COVID-19 mRNA vaccine-mediated myocarditis. Core Tip: In this review article, we aim to synthesize the current literature surrounding coronavirus disease 2019 (COVID-19) vaccine-mediated myocarditis. COVID-19 mRNA vaccination has been associated with increased cases of myocarditis, particularly in the adolescent and young adult male population. Presentation typically occurs several days following administration of the second dose of a COVID-19 mRNA vaccination. As the world continues to vaccinate against COVID-19, understanding this vaccine-related adverse event is clinically important. Potential mechanisms are reviewed, and current clinical recommendations are discussed. Original article: Morgan MC, Atri L, Harrell S, Al-Jaroudi W, Berman A. COVID-19 vaccine-associated myocarditis. World J Cardiol. 2022;14(7):382-391. DOI: 10.4330/wjc.v14.i7.382. The article was translated into Russian and published under the terms of the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license. | ||
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a sars-cov-2 | |
| 650 | 4 | |a mrna vaccine | |
| 650 | 4 | |a myocarditis | |
| 650 | 4 | |a pericarditis | |
| 653 | 0 | |a Science | |
| 653 | 0 | |a Q | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a History of scholarship and learning. The humanities | |
| 700 | 0 | |a L. Atri |e verfasserin |4 aut | |
| 700 | 0 | |a S. Harrell |e verfasserin |4 aut | |
| 700 | 0 | |a V. Al-Jaroudi |e verfasserin |4 aut | |
| 700 | 0 | |a A. Berman |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Juvenis Scientia |d Scientia Publishing House, 2019 |g 8(2022), 6, Seite 41-55 |w (DE-627)DOAJ000009229 |x 24143790 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2022 |g number:6 |g pages:41-55 |
| 856 | 4 | 0 | |u https://doi.org/10.32415/jscientia_2022_8_6_41-55 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/b1f8a1bd4a0d41d0a784d400b018aa86 |z kostenfrei |
| 856 | 4 | 0 | |u https://jscientia.org/index.php/js/user/setLocale/en_US?source=/index.php/js/article/view/179?utm_source=DOAJ |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2414-3782 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2414-3790 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2022 |e 6 |h 41-55 | ||